Skip to content
Menu
Press Releases
Filter Releases
 
EMERYVILLE, Calif., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that it will host an Investor and Analyst meeting on Monday, September 18, 2017 from 8:00 a.m. - 11:00 a.m. ET in New York, NY. The event will be hosted by members of the Adamas executive management team and will feature presentations...
Sep 13, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the compensation committee of the company's board of directors granted four new employees stock options to purchase an aggregate of 15,450 shares of the company's common stock, at a per share exercise price of $20.77, the closing...
Sep 11, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced positive topline data from the Phase 1b clinical trial of ADS-4101 (lacosamide) modified-release capsules. The study demonstrated that a 600 mg dose of ADS-4101, taken once-nightly, provided a 1.7-fold increase in average lacosamide c...
Sep 7, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Aug. 24, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved GOCOVRI (amantadine) extended release capsules (previously ADS-5102) for treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with ...
Aug 24, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the second quarter ended June 30, 2017. "This is a very exciting time for Adamas, as we are potentially at the cusp of transitioning from a company focused on product development to a c...
Aug 8, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the company will report second quarter 2017 financial results on Tuesday, August 8, 2017 after market close. Subsequently, Adamas' management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the fi...
Aug 1, 2017 General Releases HTML PDF
EMERYVILLE, Calif., July 10, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported the grant of inducement awards to its new Chief Financial Officer, Alfred G. Merriweather. The compensation committee of the company's board of directors granted Mr. Merriweather a stock option to purchase 112,500 shares of the company'...
Jul 10, 2017 General Releases HTML PDF
EMERYVILLE, Calif, June 28, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the appointment of Alfred G. Merriweather as Chief Financial Officer, reporting to Gregory T. Went, Ph.D., Chairman and Chief Executive Officer, and the retirement of William J. Dawson, its former Chief Financial Officer. Mr. Merriweath...
Jun 28, 2017 General Releases HTML PDF
--Placebo-Controlled Phase 3 Trial Demonstrated that ADS-5102 Significantly Reduced Both Dyskinesia and OFF Time at Six Months in Parkinson's Disease Patients with Levodopa-induced Dyskinesia -- -- New Drug Application for ADS-5102 Currently Under FDA Review with August 24, 2017 PDUFA Date-- EMERYVILLE, Calif., June 12, 2017 (GLOBE NEWSWIRE...
Jun 12, 2017 General Releases HTML PDF
-- New subgroup analyses showed that patients previously treated with amantadine IR received benefit of ADS-5102 comparable to patients previously treated with placebo -- -- New Drug Application supporting ADS-5102 for the treatment of levodopa-induced dyskinesia currently under FDA review with August 24, 2017, PDUFA date -- EMERYVILLE, C...
Jun 8, 2017 General Releases HTML PDF
EMERYVILLE, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., the company's Chairman and Chief Executive Officer, is scheduled to present at two upcoming investor conferences: Jefferies 2017 Global Healthcare Conference on Tuesday, June 6, 2017 at 9:30 a.m. ET J...
Jun 1, 2017 General Releases HTML PDF
-- Phase 1 results show ADS-4101 is better tolerated in healthy volunteers than equivalent doses of VIMPAT® (lacosamide) immediate-release tablets -- -- Multi-dose Phase 1b steady state study ongoing, with topline data expected in the third quarter 2017-- EMERYVILLE, Calif., May 22, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc....
May 22, 2017 General Releases HTML PDF
EMERYVILLE, Calif., May 11, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that it has entered into a $100 million royalty-backed note agreement with HealthCare Royalty Partners (HCR). Under the terms of the transaction, Adamas will receive $35 million at closing and an additional $65 million upon U.S. Fo...
May 11, 2017 General Releases HTML PDF
EMERYVILLE, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the first quarter ended March 31, 2017. "In the first quarter, we continued preparing for the potential approval and commercialization of ADS-5102, which, if approved, will be the first ...
EMERYVILLE, Calif., May 05, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported the grant of inducement awards to its new Chief Operating Officer, Richard A. King. The compensation committee of the company's board of directors granted Mr. King a stock option to purchase 168,750 shares of the company's common stock, ...
May 5, 2017 General Releases HTML PDF
Page:
...
Next Last